BN104 monotherapy

DRUG2 trials

Sponsors

Institut de Recherches Internationales Servier (I.R.I.S.), The First Affiliated Hospital of Soochow University

Conditions

ALL, AdultAML, AdultAcute LeukaemiaAcute LeukemiaKMT2A RearrangementMaintenance TherapyMenin InhibitorsNPM1 Mutation

Phase 1

A Study of BN104 in the Treatment of Acute Leukemia

Active, not recruitingNCT06052813

Institut de Recherches Internationales Servier (I.R.I.S.)Acute Leukaemia, ALL, Adult, AML, Adult +4

Start: 2023-10-19End: 2027-12-01Updated: 2026-02-25

Phase 2

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

RecruitingNCT07101497

The First Affiliated Hospital of Soochow UniversityAcute Leukemia, KMT2A Rearrangement, Maintenance Therapy +4

Start: 2025-08-01End: 2029-12-30Target: 60Updated: 2025-08-03

Related Papers

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Blood2025-11-03

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood2024-11-0511 citations